Yahoo Finance·2025-12-26 09:16Group 1 - Gilead Sciences has agreed to acquire Repare Therapeutics' RP-3467, a polymerase theta ATPase inhibitor, for a total consideration of up to $30 million, which includes a $25 million upfront payment and up to an additional $5 million based on technology transfer activities [1] - The acquisition is expected to enhance Repare's cash reserves, leading to an estimated shareholder payment of approximately $2.20 per common share upon closing the arrangement transaction [3] - Repare's CEO, Steve Forte, highlighted the significance of this transaction, marking it as the third major portfolio transaction for Repare in the year, and emphasized the potential of RP-3467 as a leading Polθ ATPase inhibitor linked to breast cancer gene mutations [4] Group 2 - On November 14, 2025, Repare announced a definitive arrangement agreement with XenoTherapeutics for the purchase of all its issued and outstanding common shares, with shareholder payments based on the company's closing cash balance after expenses and liabilities [2] - In May 2025, Repare entered into an out-licensing agreement with DCx Biotherapeutics for discovery platforms and intellectual property, indicating ongoing strategic partnerships in the biotechnology sector [5]